Stock Events

Stock Events

AIDA Pharmaceuticals 

$0
3
+$0+0% Tuesday 21:00

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
2,000
Avg. Volume
71
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30SepExpected
Q4 2006
Q1 2007
Q2 2007
Q3 2007
Q4 2007
Q1 2008
Q2 2008
-0.25
-0.14
-0.02
0.09
Expected EPS
N/A
Actual EPS
0.0848

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AIDA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a major player in the pharmaceutical industry, directly competing in multiple therapeutic areas with AIDA.
Merck
MRK
Mkt Cap214.76B
Merck operates globally in various pharmaceutical sectors, often overlapping with AIDA's product lines and research areas.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson offers a wide range of pharmaceutical products that compete with AIDA's offerings, particularly in the areas of immunology and oncology.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline competes with AIDA in several key areas, including respiratory and infectious disease treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis competes with AIDA in multiple segments such as cardiovascular, oncology, and neurology drugs.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a strong presence in biopharmaceuticals, directly competing with AIDA in areas like immunology and oncology.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb's extensive range of cancer and immunology drugs places it in direct competition with AIDA.
Sanofi
SNY
Mkt Cap124.45B
Sanofi operates globally in pharmaceuticals, competing with AIDA especially in diabetes and cardiovascular drugs.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company's focus on diabetes, cancer, and autoimmune diseases makes it a significant competitor to AIDA.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a strong portfolio in areas like oncology, cardiovascular, and respiratory diseases, competing with AIDA's products.

About

Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form, as well as rh-Apo2l, a biopharmaceutical therapy for cancers. Aida Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Hangzhou, China.
Show more...
CEO
Mr. Biao Jin
Employees
450
Country
US
ISIN
US0087211027

Listings

OTC Link
US
AIDA

0 Comments

Share your thoughts

FAQ

What is AIDA Pharmaceuticals stock price today?▼
The current price of AIDA is $0 USD — it has increased by +0% in the past 24 hours. Watch AIDA Pharmaceuticals stock price performance more closely on the chart.
What is AIDA Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AIDA Pharmaceuticals stocks are traded under the ticker AIDA.
What were AIDA Pharmaceuticals earnings last quarter?▼
AIDA earnings for the last quarter are 0.08 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does AIDA Pharmaceuticals have?▼
As of April 02, 2026, the company has 450 employees.
In which sector is AIDA Pharmaceuticals located?▼
AIDA Pharmaceuticals operates in the Health Care sector.
When did AIDA Pharmaceuticals complete a stock split?▼
The last stock split for AIDA Pharmaceuticals was on January 22, 2004 with a ratio of 1:800.
Where is AIDA Pharmaceuticals headquartered?▼
AIDA Pharmaceuticals is headquartered in Hangzhou, US.